



*Express Mail No. EL591996391US*

RECEIVED

0380

TECH CENTER 1600/2000

ATTY DOCKET NO. 5538/1010

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )

Examiner:

Serial No.: 09/610,134 ) Art Unit:

9

Filed: July 5, 2000

4

For: "METHODS AND COMPOSITIONS)  
FOR DESENSITISATION" )

4

**Assistant Commissioner for Patents  
Box IDS  
Washington, D.C. 20231**

## TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent, please find the following documents:

1. Certificate of Express Mailing;
2. Supplemental Information Disclosure Statement by Applicant;
3. USPTO Form 1449;
4. Cited References and Patents, (References 1 – 97);
5. Return Post Card.

The Assistant Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085. Reference No. 5538/1000; A duplicate of this transmittal letter is enclosed for that purpose.

Respectfully submitted,

Kathleen M. Williams, Ph.D.

PALMER AND DODGE, LLP  
One Beacon Street  
Boston, MA 02109-3190  
Telephone No: (617) 573-0451  
Fax No: (617) 227-4420



ATTY DOCKET NO. 5538/1010

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
Kay & Larche et al. )  
Serial No.: 09/610,134 )  
Filed: July 5, 2000 )  
For: "METHODS AND COMPOSITIONS)  
FOR DESENSITISATION" )

Examiner:

Art Unit:

---

Assistant Commissioner for Patents  
Box IDS  
Washington, D.C. 20231

CERTIFICATE OF EXPRESS MAILING

I hereby certify that the papers attached hereto are being deposited with the United States Postal Service using "Express Mail to Addressee" service, **Express Mail No. EL591996391US** on this date, **October 25, 2000**, postage prepaid, under 37 C.F.R. §1.10 in an envelope addressed to Assistant Commissioner for Patents, BOX IDS, Washington, D.C. 20231.

Kathleen M. Williams, Ph.D.  
Name of Person Mailing Paper

\_\_\_\_\_  
Signature of Person Mailing Paper



ATTY. DOCKET NO. 5538/1010

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )

Kay and Larche, et al. 10

Examiner:

Serial No.: 09/610,134 ) Art Unit:

Filed: July 5, 2000 )

Art Unit:

## METHODS AND COMPOSITIONS

For: "METHODS AND COMPOSITIONS)  
FOR DESENSITISATION" )

## Assistant Commissioner for Patents

## Box IDS

Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.56, 1.97 AND 1.98**

Dear Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants submit this Information Disclosure Statement pursuant to 37 C.F.R. §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office. A listing of the cited documents is also enclosed, (PTO Form 144) as well as copies of the documents in the list. Pursuant to 37 C.F.R. § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

Applicants do not intend to represent that any of the documents submitted herein is material prior art to this invention or that the list represents an exhaustive search of documents related to this invention. Applicants respectfully request that the documents submitted herein be considered and made of record in this application.

Respectfully submitted,

1 4

MATERIALS AND METHODS

Attorney of Record  
PALMER AND DOWD, LLP

PALMER AND DOUGLASS

One Beacon Street  
Boston, MA 02100-3100

BOSTON, MA 02109-3190

Telephone No. 10111.  
101-1017-327-1120.



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/610134	7/5/00	Larche	5538/1010

EXAMINER	
Amy DeCloux	
ART UNIT	PAPER NUMBER
1644	5
DATE MAILED:	

**Please find below a communication from the EXAMINER in charge of this application**

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicants are required to submit a CRF disk and paper copy of the sequences according to the attached "Notice to Comply with the Sequence Rules." Applicant is reminded of the sequence rules which require a submission for all sequences of more than 9 nucleotides or 3 amino acids (see 37 C.F.R. 1.821-1.825) and is also requested to carefully review the submitted specification for any and all sequences which require compliance with the rules.

Any inquiry concerning this communication should be directed to Examiner Amy DeCloux, Art Unit 1644, whose telephone number is (703) 306-5821.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Applicant is given TIME PERIOD of ONE EXTENDABLE MONTH, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory

time attached Notice to Comply with the reply.

October 7, 2000  
Amy DeCloux, Ph.D.  
Patent Examiner  
Art Unit 1644

PHILLIP GAMBEL  
PHILLIP GAMBEL, PH.D  
PRIMARY EXAMINER  
1644  
10/5/00

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

- 7. Other:

**Applicant Must Provide:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Autodesk Software Support, SIRA

Technical Assistance

(703) 267-3232

To Purchase PatentIn Software... 703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**